Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) insider Carl Hull acquired 175,000 shares of the firm's stock in a transaction on Monday, November 11th. The shares were bought at an average cost of $5.64 per share, with a total value of $987,000.00. Following the completion of the acquisition, the insider now owns 175,000 shares in the company, valued at $987,000. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink.
Maravai LifeSciences Stock Down 1.4 %
MRVI stock opened at $5.70 on Wednesday. The stock has a market cap of $1.44 billion, a PE ratio of -3.48 and a beta of 0.02. The firm's 50-day simple moving average is $8.03 and its 200 day simple moving average is $8.49. Maravai LifeSciences Holdings, Inc. has a fifty-two week low of $4.68 and a fifty-two week high of $11.56. The company has a quick ratio of 9.28, a current ratio of 10.00 and a debt-to-equity ratio of 0.71.
Institutional Investors Weigh In On Maravai LifeSciences
Several large investors have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. grew its holdings in Maravai LifeSciences by 6.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 946,576 shares of the company's stock worth $7,866,000 after buying an additional 56,071 shares in the last quarter. Intech Investment Management LLC acquired a new position in shares of Maravai LifeSciences during the third quarter valued at approximately $200,000. Thrivent Financial for Lutherans raised its stake in shares of Maravai LifeSciences by 14.3% in the 3rd quarter. Thrivent Financial for Lutherans now owns 214,645 shares of the company's stock worth $1,784,000 after buying an additional 26,885 shares in the last quarter. Royce & Associates LP lifted its holdings in shares of Maravai LifeSciences by 130.4% in the third quarter. Royce & Associates LP now owns 908,778 shares of the company's stock valued at $7,552,000 after buying an additional 514,332 shares during the period. Finally, Victory Capital Management Inc. boosted its position in shares of Maravai LifeSciences by 312.3% during the 3rd quarter. Victory Capital Management Inc. now owns 58,327 shares of the company's stock valued at $485,000 after purchasing an additional 44,180 shares in the last quarter. Institutional investors and hedge funds own 50.25% of the company's stock.
Wall Street Analyst Weigh In
This Bull Market Indicator called NVDA at $116
From WealthPress | Ad
Every now and again we find an investment idea so incredible we can’t help but share.
And today is one of those rare days…
Except, today we won't be giving you insight on any one particular stock…
But rather, insight on a revolutionary new stock picking indicator…
In fact, within the last year, this indicator has become famous for a multitude of reasons…
But one of the biggest was because of the buy signal it issued on October 18th, 2022.
In fact, on that very day, it said to buy NVDA at $116.37…
Anyone who did would be sitting on a tremendously large return today…
But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…
All you have to do is follow this link here
A number of equities analysts recently commented on MRVI shares. Royal Bank of Canada decreased their price target on Maravai LifeSciences from $17.00 to $13.00 and set an "outperform" rating for the company in a research note on Friday, November 8th. The Goldman Sachs Group decreased their target price on Maravai LifeSciences from $8.00 to $7.00 and set a "neutral" rating for the company in a research report on Tuesday, October 8th. Wells Fargo & Company assumed coverage on Maravai LifeSciences in a research note on Tuesday, August 27th. They set an "overweight" rating and a $10.00 price objective on the stock. UBS Group boosted their target price on shares of Maravai LifeSciences from $8.50 to $11.00 and gave the company a "neutral" rating in a research note on Thursday, August 8th. Finally, Morgan Stanley downgraded shares of Maravai LifeSciences from an "overweight" rating to an "equal weight" rating and reduced their price target for the stock from $11.00 to $10.00 in a research report on Tuesday, August 13th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $10.33.
Read Our Latest Analysis on MRVI
About Maravai LifeSciences
(
Get Free Report)
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
